NAD+ and NR for Multiple Sclerosis: The NORSEMAN Study

NAD+ is not an established treatment for multiple sclerosis. There is a real human research program: NORSEMAN is testing oral nicotinamide riboside (NR) alongside standard care in progressive MS. Its registration describes a planned trial, not a demonstrated benefit. When checked on October 14, 2026, the official record had no results posted ¹².

That is a more useful answer than either dismissing the question or presenting an NAD+ infusion as proven neuroprotection. The NAD+, NR and NMN comparison explains why these names cannot be substituted for one another when interpreting a study.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

MadeMed

NAD+ injection & nasal spray, in 23 states

See MadeMed↗

Why NAD-related research is being done in MS

The NORSEMAN investigators describe mitochondrial dysfunction and impaired neuronal energy handling as reasons to investigate NAD-related pathways in MS. The hypothesis is that an oral precursor could support cellular processes involved in progressive disability ¹. A plausible mechanism explains why a study is worth doing; it does not establish that the treatment works.

Animal research offers additional rationale. One experiment examined NAD+ together with atorvastatin in mice with experimental autoimmune encephalomyelitis, an inflammatory model used in MS research. The investigators reported effects on disease development and related signaling measures ³.

That experiment did not test a telehealth injection program in people with MS. The animal model, intervention and outcomes all differ. It also cannot establish that someone taking a statin should add NAD+, or that a combination used in mice is appropriate for a patient. Those are separate clinical questions.

What NORSEMAN is designed to answer

The hospital's trial description specifies oral NR as an add-on to standard care, with a planned 300 participants assigned to NR or placebo over 30 months ¹. The registry identifies a phase-II randomized study and an estimated enrollment, rather than a report of 300 people already completing treatment ².

Its main outcome concerns sustained disability progression, assessed using disability, walking or hand-function measures. Secondary outcomes include MRI and progression measures ². These are more clinically relevant than asking only whether blood NAD+ rises.

The distinction between a study question and a study result is essential. A trial title saying “NR supplementation in progressive MS” does not mean supplementation has already slowed progression. A registration identifies what researchers intend to test, how they plan to assess it and where results should eventually be reported.

What can we say about the study's current status?

The official record inspected for this article had no posted results. It listed estimated completion dates in 2027, but its last update was posted in January 2024 ². That makes the dates and recruitment label historical registry information, not a guarantee about today's enrollment or timetable.

Anyone interested in participating should contact the study team through the official hospital or registry listing. Eligibility and current recruitment need confirmation from the investigators. A clinic selling a similarly named supplement is not a source of information about trial enrollment.

This guide will need a substantive update when results become available. In the meantime, it would be premature to turn the trial protocol into an expected improvement, a success rate or a consumer treatment schedule.

Does NR research support NAD+ shots or IV therapy?

No result from a study of oral NR can automatically validate an NAD+ injection, infusion or nasal preparation. A treatment claim needs the actual molecule, route, population and outcome to match. The NAD+ injection review and IV evidence guide explain the limits of those routes separately.

The study protocol is also not a self-treatment prescription. The fact that researchers selected an amount for supervised study does not establish a therapeutic dose for someone with a different MS course, other medicines or other medical conditions. This article gives no validated NAD+ or NR dose for MS because a demonstrated treatment regimen is not established by the sources discussed here.

Disability progression and fatigue are different outcomes

A person may be interested in an NAD-related product because of fatigue, walking difficulty, cognition or concern about progression. Those are distinct goals. A change in perceived energy cannot by itself establish that MS activity or long-term disability has improved.

Our NAD+ energy review addresses symptom claims, while the brain-fog guide explains why cognitive trials in other populations do not answer every neurological question. Avoid treating a positive testimonial about one symptom as a result on the outcome NORSEMAN is studying.

Before considering an optional product, tell the MS team which difficulty you want help with. Ask how that problem is being assessed and which established options apply. A research hypothesis should add clarity to that conversation, not displace it.

Keep established MS care in place

NIH explains that MS treatment can reduce relapses and slow the accumulation of disability, with options depending on the disease course and individual circumstances ⁴. An experimental precursor should not replace a disease-modifying treatment or lead someone to postpone assessment of new neurological symptoms.

Bring the complete product label and current medication list to the neurologist or pharmacist. Ask whether a proposed add-on has evidence in people taking the same therapies, who would monitor it and what would lead to stopping it. The NMN interaction guide illustrates why missing interaction research is not proof that every precursor combination is harmless.

There is a meaningful MS research question here, and NORSEMAN is attempting to answer it with clinical outcomes. Until results establish what happened, “under investigation” is the accurate description—not “proven to repair myelin,” “slows MS” or a reason to purchase an NAD+ injection course.